Eads & Heald Investment Counsel decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,419 shares of the company’s stock after selling 860 shares during the quarter. Johnson & Johnson comprises 1.4% of Eads & Heald Investment Counsel’s holdings, making the stock its 12th biggest position. Eads & Heald Investment Counsel’s holdings in Johnson & Johnson were worth $2,172,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently modified their holdings of JNJ. Lenox Wealth Advisors Inc. increased its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares in the last quarter. Ullmann Financial Group Inc. acquired a new position in Johnson & Johnson during the 1st quarter valued at approximately $186,000. Taylor Wealth Management Partners increased its stake in Johnson & Johnson by 19.8% during the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after purchasing an additional 250 shares in the last quarter. Finally, Puplava Financial Services Inc. acquired a new position in Johnson & Johnson during the 2nd quarter valued at approximately $202,000. Institutional investors and hedge funds own 66.06% of the company’s stock.
Johnson & Johnson (JNJ) opened at $139.56 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The stock has a market cap of $374,930.72, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 2.84 and a beta of 0.82. Johnson & Johnson has a twelve month low of $109.32 and a twelve month high of $144.35.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $1.68 earnings per share. equities research analysts predict that Johnson & Johnson will post 7.28 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.41%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 58.33%.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/11/12/johnson-johnson-jnj-position-lowered-by-eads-heald-investment-counsel.html.
A number of brokerages have issued reports on JNJ. J P Morgan Chase & Co upped their price target on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research note on Wednesday, August 16th. Jefferies Group LLC set a $145.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Tuesday, August 15th. UBS AG reaffirmed a “buy” rating and issued a $148.00 price objective (up from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. BTIG Research downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price objective on the stock. in a report on Friday, July 21st. Finally, Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price objective on the stock. in a report on Monday, September 18th. Four analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $143.70.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.